GlassScriptPhysician profile
Shari D Lurie
NPI 1154368702
$328.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $26.98 · 2021: $93.14 · 2022: $61.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $95.92 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $39.20 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $36.71 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.84 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.15 | 2022 | |
| Bioventus LLC | $21.64 | 2022 | |
| Zyla Life Sciences, INC. | $19.42 | 2019 | |
| Lilly USA, LLC | $18.51 | 2019 | |
| Pfizer INC. | $17.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.14 | 2020 | |
| Indivior INC. | $12.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Lurie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.